



May 30, 2022

The Listing Department  
BSE Limited  
Phiroz Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai - 400 001

**Ref: Security Code No. 530233**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting dated May 30, 2022**

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. **May 30, 2022**) has inter-alia, approved the following:

**1. Annual Audited Financial Results:**

Approved the Audited Standalone Financial Results of the Company for the quarter & year ended on March 31, 2022 including notes thereon for the financial year ended March 31, 2022 and the Statement of Cash Flow and the Statement of Assets and Liabilities as at March 31, 2022 on that date, as recommended by the Audit Committee.

In compliance with Regulation 30, please find enclosed the following documents prepared in Compliance with Regulations 33 of the Listing Regulations and SEBI Circulars, as applicable:

- Audited Standalone Financial Results for the quarter and year ended March 31, 2022 including the Statement of Cash Flow and the Statement of Assets and Liabilities as at March 31, 2022. (**Annexure "A"**)
- Auditor's Report by M/s Khurdia Jain & Co., Chartered Accountants, Mumbai, the Statutory Auditors of the Company on the Financial Results for the quarter and year ended March 31, 2022 (**Annexure "B"**)
- Declaration regarding Auditor's report with unmodified opinion pursuant to Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015 (**Annexure "C"**)

The results are also being uploaded on website of the Company at [www.aurolabs.com](http://www.aurolabs.com).

**2. Directors' report**

Considered and approved the draft Director's report along with annexures, Director's responsibility statement, Management Discussion & analysis and Corporate Governance report for the financial year ended March 31, 2022.



3. **Secretarial Auditors**

Considered and approved re-appointment of M/s GMJ & Associates as the Secretarial Auditors of the Company for the financial year 2022-23.

4. **Internal Auditors**

Considered and approved re-appointment of M/s Pokharna & Associates as the Internal Auditors of the Company for the financial year 2022-23.

5. **Cost Auditors**

Considered and approved the re-appointment of M/s. Poddar & Co., (FRN: 101734), Cost Accountants, Mumbai as the Cost Auditors of the Company for conducting the audit of cost records for the financial year 2022-2023.

6. **Statutory Auditors**

Subject to the approval of the members of the Company at the ensuing AGM, considered and recommended appointment of M/s Kothari Jain & Associates (FRN 113041W) as the Statutory Auditors of the Company for a period of 5(five) years i.e from the conclusion of 33<sup>rd</sup> AGM till the conclusion of 38<sup>th</sup> AGM of the Company.

Further, the details as required to be disclosed in terms of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September, 2015 are given in "Annexure D" as enclosed to this letter.

7. **Related Party Transactions Policy**

Considered and approved amendments to the Related Party Transactions Policy. A copy of the policy is made available on the website of the Company at [www.aurolabs.com](http://www.aurolabs.com).

8. **Policy on performance evaluation**

Considered and approved Policy on performance evaluation, as recommended by the Nomination and Remuneration Committee. A copy of the policy is made available on the website of the Company at [www.aurolabs.com](http://www.aurolabs.com).

9. **Dissolution of the CSR Committee**

Considered and approved dissolution of the Corporate Social Responsibility Committee with effect from May 30, 2022 in terms of the Section 135(9) of the Companies Act, 2013 and approved vesting of all powers of the Committee with the Board of Directors.

10. **Amendment of Memorandum of Association**

Approved amendment of Memorandum of Association of the company to align with the Companies Act, 2013, subject to the approval of members of the Company at the ensuing Annual General meeting.

11. **Re-appointment of Director**

Based on recommendation of Nomination and Remuneration Committee, considered and recommended re-appointment of Mr. Kiran Suresh Kulkarni, who retires by rotation, and being eligible, offered himself for re-appointment, subject to the approval of members in the forthcoming AGM.



**12. Resignation of Company Secretary and Compliance officer of the Company**

Accepted resignation of CS Shanu Nag (M.No. A36292) as the Company Secretary and Compliance officer of the Company effective from the close of business hours on May 30, 2022.

Further, the details as required to be disclosed in terms of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September, 2015 are given in "Annexure D" as enclosed to this letter.

**13. Appointment of Company Secretary and Compliance officer of the Company**

Based on recommendation of Nomination and Remuneration Committee, considered and approved appointment of CS Sweta Agarwal, Fellow member of the Institute of Company Secretaries of India (M.No. F10753) as the Company Secretary and Compliance officer of the Company and designated as a Key Managerial personnel with effect from May 31, 2022.

Further, the details as required to be disclosed in terms of SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September, 2015 are given in "Annexure D" as enclosed to this letter.

**14. Notice of 33<sup>rd</sup> Annual General Meeting**

Approved convening of the 33<sup>rd</sup> Annual General Meeting of the Company for the financial year ended March 31, 2022 on Wednesday, July 20, 2022.

The Annual General Meeting shall be held by Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") in accordance with the relevant Circulars issued by the Ministry of Corporate Affairs and SEBI to transact the business as contained in the Notice convening the AGM.

The meeting of the Board of Directors commenced at 02.00 PM and concluded at 04.00 PM.

This intimation is also being uploaded on Company's website at [www.aurolabs.com](http://www.aurolabs.com).

The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

Kindly take the above on your record.

Thanking you,

Yours Faithfully,

For, Auro Laboratories Limited

(Siddhartha Deorah)

Whole Time Director

DIN: 00230796



Encl: A/a

**AURO LABORATORIES LIMITED**

CIN NO. :- L33126MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

**ANNEXURE - I**

PART - I		(Rs. in Lakhs except EPS)				
		<b>STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2022</b>				
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2022 (Ref. Note 4)	31.12.2021 (Unaudited)	31.03.2021 (Ref. Note 4)	31.03.2022 (Audited)	31.03.2021 (Audited)
1	Revenue from Operations	1,788.35	1,213.65	1,356.46	5,086.58	5,425.18
2	Other Income	28.18	2.10	17.17	109.26	75.78
3	<b>Total Income (1 + 2)</b>	<b>1,816.51</b>	<b>1,215.75</b>	<b>1,373.63</b>	<b>5,195.83</b>	<b>5,500.96</b>
4	<b>Expenses</b>					
	a. Cost of raw material consumed	1209.23	822.00	618.36	3,373.88	2,743.09
	b. Purchase of Stock-in-trade	0.00	0.95	0.60	2.40	21.03
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	67.32	-44.32	76.05	(98.16)	90.71
	d. Employee benefits expense	188.68	149.86	178.58	624.00	603.62
	e. Finance Cost	39.63	16.48	25.03	82.64	45.83
	f. Depreciation and amortisation expenses	23.72	26.00	27.56	101.72	103.56
	g. Other Expenses	232.94	163.30	278.18	721.95	842.58
	<b>Total Expenses (4)</b>	<b>1,761.52</b>	<b>1,134.27</b>	<b>1,104.36</b>	<b>4,808.43</b>	<b>4,450.42</b>
5	<b>Profit / (Loss) before exceptional and extraordinary items and tax (3± 4)</b>	<b>54.99</b>	<b>81.48</b>	<b>269.27</b>	<b>387.40</b>	<b>1,050.54</b>
6	Exceptional items					
7	<b>Profit / (Loss) before tax (5 ± 6)</b>	<b>54.99</b>	<b>81.48</b>	<b>269.27</b>	<b>387.40</b>	<b>1,050.54</b>
8	<b>Tax expense</b>					
	(a) Current tax expenses for current year	13.25	20.37	104.91	106.59	320.09
	(b) MAT credit (where applicable)					
	(c) Deferred tax	(3.76)	-	12.49	(3.76)	12.49
9	<b>Profit / (Loss) for the period from continuing operation (7± 8)</b>	<b>46.50</b>	<b>61.11</b>	<b>151.87</b>	<b>284.47</b>	<b>717.96</b>
10	<b>Profit / (Loss) for discontinuing operations</b>					
11	Tax expense of discontinuing operations					
12	<b>Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)</b>					
13	<b>Profit / (Loss) for the period (after tax) (9 ± 12)</b>	<b>46.50</b>	<b>61.11</b>	<b>151.87</b>	<b>284.47</b>	<b>717.96</b>
14	<b>Other Comprehensive Income</b>	<b>11.14</b>	<b>6.07</b>	<b>1.76</b>	<b>11.14</b>	<b>1.76</b>
15	<b>Total Comprehensive Income for the period (13 ± 14)</b>	<b>56.64</b>	<b>67.18</b>	<b>153.63</b>	<b>295.61</b>	<b>719.72</b>
16	<b>Paid-up equity share capital</b> (Face value of Rs. 10 each)	<b>623.25</b>	<b>623.25</b>	<b>623.25</b>	<b>623.25</b>	<b>623.25</b>
17	<b>Other Equity</b>				<b>2,528.85</b>	<b>2,235.01</b>
18	<b>Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):</b>					
	(a) Basic	0.73	0.98	2.44	4.56	11.62
	(b) Diluted	0.73	0.98	2.44	4.56	11.62



**Notes on financial results:-**

- 1) The above audited financial results for the quarter and year ended 31st March, 2022 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 30th May, 2022.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) The above audited results, published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been prepared in accordance with Indian Accounting Standards (IND AS) notified under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015; Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and guidelines issued by the Securities and Exchange Board of India (SEBI) and other accounting principles generally accepted in India.
  - 4) Figures of the Quarter ended on 31st March, 2022 & 31st March, 2021 are the balancing figures between audited figures in respect of the full financial year and the published year to the date upto the third quarter of the respective financial year.
- 5) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.

**FOR & BEHALF OF BOARD OF DIRECTORS**

**AURO LABORATORIES LIMITED**

*Siddhartha Decrah*

(SIDDHARTHA DECRAH)

WHOLE TIME DIRECTOR

DIN: 00230796



Place : Mumbai

Date : 30.05.2022

<b>Auro Laboratories Limited</b>		
<b>Statement of Assets and Liabilities (Ind AS)</b>		
Particulars	(Rs. in Lakh)	
	As at 31.03.2022 Audited	As at 31.03.2021 Audited
<b>A ASSETS</b>		
<b>1. Non-Current Assets</b>		
(a) Property, Plant and Equipment	1,350.81	1,355.67
(b) Capital Work -in-Progress	367.50	13.40
(c) Investment Property	-	-
(d) Financial Assets		
(i) Investments	4.88	4.88
(ii) Loans	-	-
(iii) Others	-	-
(e) Other non-current assets	-	-
<b>2. Current assets</b>		
(a) Inventories	425.46	254.67
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	1,361.33	729.90
(iii) Cash and cash equivalents	521.16	1,082.14
(iv) Bank balances other than (iii) above	718.40	371.49
(v) Loans	-	-
(vi) Others	736.48	377.13
(c) Other Current Assets	-	-
<b>TOTAL ASSETS</b>	<b>5496.02</b>	<b>4189.28</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>1. Equity</b>		
(a) Equity Share Capital	623.25	623.25
(b) Other Equity	2,528.85	2,235.01
<b>2. Liabilities</b>		
(I) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	84.95	203.88
(ii) Other Financial Liabilities	81.26	112.00
(b) Provisions		
(c) Deferred Tax Liabilities (Net)	164.65	168.40
(II) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,211.56	-
(i) Trade Payables	486.22	574.96
(b) Other Current Liabilities	163.80	166.88
(c) Provisions	151.48	104.90
(d) Current Tax Liabilities (net)	-	-
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>5496.02</b>	<b>4189.28</b>

FOR & BEHALF OF BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED

(SIDDHARTHA DEORAH)  
WHOLE TIME DIRECTOR  
DIN: 00230796



Place : Mumbai  
Date : 30.05.2022

## Cash Flow Statement


(Rs. In Lakh)

Particulars	For the year ended 31.03.2022		For the year ended 31.03.2021	
	Amount	Amount	Amount	Amount
<b>A. Cash flow from operating activities</b>				
Net Profit / (Loss) before extraordinary items and tax		387.40		1,050.54
Add: Adjustments for:				
Depreciation and amortisation	101.72		103.56	
Other Non Cash Items	11.14		1.76	
Finance costs	82.64	195.50	45.84	151.16
		582.90		1,201.70
Less: Adjustment for:				
Interest income	35.08		18.01	
Dividend income	0.05	35.13	0.03	18.04
<b>Operating profit / (loss) before working capital changes</b>		<b>547.77</b>		<b>1,183.66</b>
Changes in working capital:				
Adjustments for (Increase) / decrease in operating assets:				
Inventories	(170.79)		151.59	
Trade receivables	(631.44)		(151.91)	
Loans and advances	(350.95)		(138.07)	
Other Bank Balance	(8.39)		3.10	
Other non-current assets		(1,161.58)		(135.29)
		(613.81)		1,048.37
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	(88.74)		101.13	
Other current liabilities	(3.08)		36.24	
Other long-term liabilities				
Short-term provisions	46.58		95.82	
Long-term provisions				
		(45.24)		233.19
		(659.05)		1,281.56
Cash flow from extraordinary items				
Cash generated from operations		(659.05)		1,281.56
Net income tax (paid) / refunds				
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>(659.05)</b>		<b>1,281.56</b>



<b>B. Cash flow from investing activities</b>			
Capital expenditure on fixed assets, including capital advance	(460.96)		(37.51)
Proceeds from sale of fixed assets			
Interest received			
- Others	35.08		18.01
Dividend received			
- Others	0.05		0.03
		(425.83)	(19.47)
Net income tax (paid) / refunds		(108.45)	(331.32)
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(534.28)</b>	<b>(350.79)</b>
<b>C. Cash flow from financing activities</b>			
Proceeds from long-term borrowings			
Repayment of borrowings & Net increase / (decrease) in working capital borrowings	(42.10)		(43.12)
Proceeds from other short-term borrowings	661.66		
Repayment of other short-term borrowings	473.07		66.02
Finance cost	(30.73)		(22.62)
	(82.64)		(45.84)
		979.26	(45.56)
Cash flow from extraordinary items			
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>979.26</b>	<b>(45.56)</b>
<b>Net increase/(decrease) in Cash &amp; cash equivalents (A+B+C)</b>		<b>(214.07)</b>	<b>885.22</b>
Cash and cash equivalents at the beginning of the year		1,453.63	568.41
<b>Cash and cash equivalents at the end of the year</b>		<b>1,239.56</b>	<b>1,453.63</b>

FOR & BEHALF OF BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED

  
(SIDDHARTHA DEORAH)  
WHOLE TIME DIRECTOR  
DIN: 00230796



Place : Mumbai  
Date : 30.05.2022





**KHURDIA JAIN & CO.**  
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF THE STANDALONE  
FINANCIAL RESULTS OF THE COMPANY**

**To the Board of Directors of Auro Laboratories Limited**

We have audited the accompanying Statement of Standalone Financial Results of Auro Laboratories Limited ("the Company") for the quarter and year ended March 31, 2022; attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

**Opinion on Annual Financial Results**

1. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - (i) is presented in accordance with requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, and
  - (ii) gives a true and fair view, in conformity with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the profit, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2022.

**Basis of opinion**

2. We conducted our audit in accordance with the Standards on Auditing issued by Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement(s).



An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statements.

We believe that the evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion

### **Key Audit Matters**

3. Key Audit Matters are those matters that, in our professional judgement, were of most significance in our audit of the Ind-AS financial statements of the current period. These matters were addressed in the context of our audit of the Ind-AS financial statements as a whole, and informing our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to be communicated in our report.

### **Management's and Those Charged with Governance Responsibilities for the Statement**

4. This Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including



SEBI Circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Statement**

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures



responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
  - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such, disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably



be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

11. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement as it relates to the quarter ended March 31, 2022, has been compiled from the related interim condensed standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2022, had been compiled from the related annual standalone financial statements prepared under Section 133 of the Companies Act, 2013 read with rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim condensed standalone financial statements and annual standalone financial statements.

Further, we report that the figures for the quarter ended March 31, 2022 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2022 and the published year to date figures up to December 31, 2021 being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated above as required under the Listing Regulations and circular.

For Khurdia Jain & Co.  
Chartered Accountants  
(Firm Reg. No. 120263W)

  
(Sampat Khurdia)


Partner

Membership No. 033615

Place: Mumbai

Date: 30/05/2022

UDIN: 22033615AJWFXT3440





Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,  
Worli, Mumbai - 400 030. India  
Tel. : + 91 22 6663 5456  
Fax : +91 22 6663 5460  
E-mail : auro@aurolabs.com  
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :  
K-56, M. I. D. C. Tarapur,  
Dist. Palghar, Maharashtra - 401506.  
CIN No. L33125MH1989PLC051910

Date: May 30, 2022

The Listing Department  
BSE Limited  
Phiroz Jeejeebhoy Towers  
Dalal Street, Mumbai - 400 001

Reg: Security Code No. 530233

Dear Sir,

**Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI / LAD-NRO / GN / 2016-17 / 001 dated May 25, 2016 read with SEBI Circular No. CIR / CED / CMD / 56 / 2016 dated May 27, 2016, we hereby declared that the Statutory Auditors of the Company M/s. Khurdia Jain & Co, Chartered Accountants, Mumbai (Firm Registration No. 120263W) have issued the Audit Report with an unmodified Opinion on the Financial results for the quarter & year ended on March 31, 2022.

Kindly take the same on your record.

Thanking you,

For Auro Laboratories Limited

(Siddhartha Deorah)  
Whole Time Director  
DIN: 00230796



**ANNEXURE "D"- DETAILS REQUIRED IN TERMS OF SEBI CIRCULAR NO. CIR/CFD/CMD/4/2015  
DATED SEPTEMBER 09, 2015**

**I. Appointment of Statutory Auditors of the Company**

Reason for change viz, appointment, death, resignation, removal, or otherwise	<p>M/s. Khurdia Jain &amp; Co., Chartered Accountants, were appointed as Statutory Auditors of the Company at the 28<sup>th</sup> Annual General Meeting ('AGM') held on September 29, 2017 for a period of 5 years, i.e. up to the conclusion of 33<sup>rd</sup> AGM. M/s. Khurdia Jain &amp; Co., Chartered Accountants, will complete their present term and are retiring at the ensuing AGM completing a block of five years. M/s. Khurdia Jain &amp; Co, have submitted their unwillingness to continue as the Statutory Auditors of the Company for a further period of five years.</p> <p>The Board of Directors of the Company based on the recommendation of the Audit Committee, recommended for the approval of the members, the appointment of M/s. Kothari Jain &amp; Associates, Chartered Accountants, Mumbai (FRN. 113041W), as the Statutory Auditors of the Company for a period of five years from the conclusion of the ensuing AGM till the conclusion of the 38<sup>th</sup> AGM.</p>
Date of Appointment/ Cessation & term of appointment	To be appointed at the ensuing Annual General meeting on approval of the members of the Company, for a period of five years from the conclusion of the ensuing AGM till the conclusion of the 38 <sup>th</sup> AGM.
Brief Profile	<p>M/s. Kothari Jain &amp; Associates (FRN 113041W), a firm of Chartered Accountants, was established in the year 1992 by Mr. Sunil Kumar Kothari, a Fellow Chartered Accountant in active practice for more than 25 years.</p> <p>The firm has a team of skilled and experienced personnel having in depth knowledge and experience in providing multitude of services consisting of Statutory Audits, Corporate Finance, tax Planning, due diligence, consultancy etc.</p>
Disclosure of relationship (in case of appointment of Director)	Not applicable

**II. Resignation of CS Shanu Nag (M.No. A36292), Company Secretary and Compliance officer of the Company**

Reason for change viz, appointment, death, resignation, removal, or otherwise	<p>CS Shanu Nag was appointed as the Company Secretary and Compliance Officer in terms of Section 203 of the Companies Act, 2013 and Regulation 6 of the SEBI (LODR) Regulations, 2015 with effect from October 01, 2014.</p> <p>She has submitted her resignation from the said position on account of personal reasons.</p>
Date of Appointment/ Cessation & term of appointment	Close of business hours on May 30, 2022



Brief Profile	Not applicable
Disclosure of relationship (in case of appointment of Director)	Not applicable

### III.Appointment of CS Sweta Agarwal (M.No. F10753) as the Company Secretary and Compliance officer of the Company

Date of Birth, Age	October 21, 1990 (31years)
Qualification	CS Sweta Agarwal is a qualified Company Secretary from the Institute of Company Secretaries of India holding Membership number F10753.  She also holds a Bachelor's degree in Commerce from Ranchi University.
Experience	Overall experience of 7 years in corporate Secretarial field. She has previously worked with Special Blasts Limited as the Company Secretary and Ashoka Refineries Limited as the Company Secretary & Compliance officer of the Company.
Reason for change viz, appointment, <del>death</del> , <del>resignation</del> , <del>removal</del> , or <del>otherwise</del>	Appointment as the Company Secretary and Compliance officer of the Company and designated as a Key Managerial personnel
Date of Appointment/ Cessation & term of appointment	Appointed with effect from May 31, 2022
Brief Profile	As detailed above
Disclosure of relationship (in case of appointment of Director)	Not applicable

